ciglitazone has been researched along with Diabetic Glomerulosclerosis in 3 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
| Excerpt | Relevance | Reference |
|---|---|---|
| " CZ ameliorated decrease bioavailability of NO in the diabetic animal." | 1.35 | Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. ( Kumar, M; Kundu, S; Rodriguez, WE; Sen, U; Tyagi, N; Tyagi, SC, 2008) |
| " Long-term administration (12 and 20 weeks) of ciglitazone significantly improved the blood glucose of most of the treated db/db mice." | 1.27 | Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice. ( Chang, AY; Diani, AR; Gilchrist, BJ; Hearron, AE; Jodelis, K; Peterson, T; Sawada, G; Wyse, BM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sen, U | 1 |
| Rodriguez, WE | 1 |
| Tyagi, N | 1 |
| Kumar, M | 1 |
| Kundu, S | 1 |
| Tyagi, SC | 1 |
| Ohga, S | 1 |
| Shikata, K | 1 |
| Yozai, K | 1 |
| Okada, S | 1 |
| Ogawa, D | 1 |
| Usui, H | 1 |
| Wada, J | 1 |
| Shikata, Y | 1 |
| Makino, H | 1 |
| Diani, AR | 1 |
| Peterson, T | 1 |
| Sawada, G | 1 |
| Jodelis, K | 1 |
| Wyse, BM | 1 |
| Gilchrist, BJ | 1 |
| Hearron, AE | 1 |
| Chang, AY | 1 |
3 other studies available for ciglitazone and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epinephrine; Gene E | 2008 |
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, E | 2007 |
Ciglitazone, a new hypoglycemic agent. 5. Effect on renal lesions in C57BL/KsJ-db/db mice.
Topics: Animals; Blood Glucose; Diabetic Nephropathies; Drug Evaluation, Preclinical; Glomerular Mesangium; | 1986 |